Cardiac hypertrophy: The good, the bad and the ugly

被引:1153
作者
Frey, N [1 ]
Olson, EN
机构
[1] Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA
[2] Heidelberg Univ, Dept Cardiol Innere Med 3, D-69115 Heidelberg, Germany
关键词
heart failure; treatment; signaling; cardiomyocyte;
D O I
10.1146/annurev.physiol.65.092101.142243
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Cardiac hypertrophy is the heart's response to a variety of extrinsic and intrinsic stimuli that impose increased biomechanical stress. While hypertrophy can eventually normalize wall tension, it is associated with an unfavorable outcome and threatens affected patients with sudden death or progression to overt heart failure. Accumulating evidence from studies in human patients and animal models suggests that in most instances hypertrophy is not a compensatory response to the change in mechanical load, but rather is a maladaptive process. Accordingly, modulation of myocardial growth without adversely affecting contractile function is increasingly recognized as a potentially auspicious approach in the prevention and treatment of heart failure. In this review, we summarize recent insights into hypertrophic signaling and consider several novel antihypertrophic strategies.
引用
收藏
页码:45 / 79
页数:37
相关论文
共 224 条
  • [51] Dufner A, 1999, MOL CELL BIOL, V19, P4525
  • [52] Endothelin-induced cardiac myocyte hypertrophy: role for focal adhesion kinase
    Eble, DM
    Strait, JB
    Govindarajan, G
    Lou, L
    Byron, KL
    Samarel, AM
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2000, 278 (05): : H1695 - H1707
  • [53] Inhibition of Na+-H+ exchange prevents hypertrophy, fibrosis, and heart failure in β1-adrenergic receptor transgenic mice
    Engelhardt, S
    Hein, L
    Keller, U
    Klämbt, K
    Lohse, MJ
    [J]. CIRCULATION RESEARCH, 2002, 90 (07) : 814 - 819
  • [54] INCREASED MESSENGER-RNA LEVEL OF THE INHIBITORY-G PROTEIN ALPHA-SUBUNIT GI-ALPHA-2 IN HUMAN END-STAGE HEART-FAILURE
    ESCHENHAGEN, T
    MENDE, U
    NOSE, M
    SCHMITZ, W
    SCHOLZ, H
    HAVERICH, A
    HIRT, S
    DORING, V
    KALMAR, P
    HOPPNER, W
    SEITZ, HJ
    [J]. CIRCULATION RESEARCH, 1992, 70 (04) : 688 - 696
  • [55] Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress
    Esposito, G
    Rapacciuolo, A
    Prasad, SVN
    Takaoka, H
    Thomas, SA
    Koch, WJ
    Rockman, HA
    [J]. CIRCULATION, 2002, 105 (01) : 85 - 92
  • [56] An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy
    Fatkin, D
    McConnell, BK
    Mudd, JO
    Semsarian, C
    Moskowitz, IGP
    Schoen, FJ
    Giewat, M
    Seidman, CE
    Seidman, JG
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (11) : 1351 - 1359
  • [57] The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus
    Finck, BN
    Lehman, JJ
    Leone, TC
    Welch, MJ
    Bennett, MJ
    Kovacs, A
    Han, XL
    Gross, RW
    Kozak, R
    Lopaschuk, GD
    Kelly, DP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (01) : 121 - 130
  • [58] Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
    Fingar, DC
    Salama, S
    Tsou, C
    Harlow, E
    Blenis, J
    [J]. GENES & DEVELOPMENT, 2002, 16 (12) : 1472 - 1487
  • [59] Phospholamban and cardiac contractility
    Frank, K
    Kranias, EG
    [J]. ANNALS OF MEDICINE, 2000, 32 (08) : 572 - 578
  • [60] Decoding calcium signals involved in cardiac growth and function
    Frey, N
    McKinsey, TA
    Olson, EN
    [J]. NATURE MEDICINE, 2000, 6 (11) : 1221 - 1227